LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has been granted Innovation Passport designation for OTL-201, an investigational haemopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). The designation was awarded under the recently refreshed Innovative Licensing and Access Pathway (ILAP) in the UK, which provides a single integrated platform for sustained collaboration between developers, t ...